Scancell - Public Comps and Valuation Multiples

Scancell Overview

About Scancell

Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.

Founded

2008

HQ

Employees

Website

scancell.co.uk

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue $3.8M

LTM EBITDA -$16.9M

EV

$131M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Scancell Financials

As of September 2025, Scancell reported last 12-month revenue of $3.8M and EBITDA of -$16.9M.

In the same period, Scancell generated $3.7M in LTM gross profit and -$15.3M in net income.

See Scancell valuation multiples based on analyst estimates

Scancell P&L

In the most recent fiscal year, Scancell reported revenue of $6.3M and EBITDA of -$16.9M.

Scancell expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Scancell valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$3.8M	XXX	$6.3M	XXX	XXX	XXX
Gross Profit	$3.7M	XXX	$6.0M	XXX	XXX	XXX
Gross Margin	96%	XXX	95%	XXX	XXX	XXX
EBITDA	-$16.9M	XXX	-$16.9M	XXX	XXX	XXX
EBITDA Margin	-440%	XXX	-270%	XXX	XXX	XXX
EBIT	-$18.3M	XXX	-$20.0M	XXX	XXX	XXX
EBIT Margin	-477%	XXX	-318%	XXX	XXX	XXX
Net Profit	-$15.3M	XXX	-$16.4M	XXX	XXX	XXX
Net Margin	-398%	XXX	-260%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Scancell including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $3.8M. EBITDA for the last twelve months was -$16.9M. In the most recent fiscal year, Scancell achieved $6.3M in revenue and -$16.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$3.8M	Analyst estimates available to subscribers	$6.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$3.7M	Analyst estimates available to subscribers	$6.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	96.3% gross margin	Analyst estimates available to subscribers	94.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$16.9M	Analyst estimates available to subscribers	-$16.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-440.3% EBITDA margin	Analyst estimates available to subscribers	-269.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$18.3M	Analyst estimates available to subscribers	-$20.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-477.1% EBIT margin	Analyst estimates available to subscribers	-318.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$15.3M	Analyst estimates available to subscribers	-$16.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-398.3% net profit margin	Analyst estimates available to subscribers	-260.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Scancell

This financial data table provides comprehensive performance metrics for Scancell, a company based in United Kingdom of Great Britain and Northern Ireland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Scancell generated $3.8M in revenue over the last twelve months.
The company achieved -$16.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $3.7M.
Net income over the last twelve months reached -$15.3M.

Fiscal Year Performance

In the most recent fiscal year, Scancell reported $6.3M in total revenue.
Fiscal year EBITDA was -$16.9M.
The company maintained a gross profit margin of 94.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was -269.7%.
Net profit margin reached -260.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Scancell. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Scancell Stock Performance

Scancell has current market cap of GBP 99.1M (or $132M), and EV of GBP 98.5M (or $131M).

Market Cap Evolution

Scancell Stock Data

As of October 17, 2025, Scancell's stock price is GBP 0 (or $0).

See Scancell trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$131M	$132M	XXX	XXX	XXX	XXX	$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Scancell Valuation Multiples

Scancell's trades at n/a EV/Revenue multiple, and -9.1x EV/EBITDA.

See valuation multiples for Scancell and 15K+ public comps

Scancell Financial Valuation Multiples

As of October 17, 2025, Scancell has market cap of $132M and EV of $131M.

Equity research analysts estimate Scancell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Scancell has a P/E ratio of -8.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$132M	XXX	$132M	XXX	XXX	XXX
EV (current)	$131M	XXX	$131M	XXX	XXX	XXX
EV/Revenue	34.2x	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-7.8x	XXX	-9.1x	XXX	XXX	XXX
EV/EBIT	-7.2x	XXX	-6.1x	XXX	XXX	XXX
EV/Gross Profit	35.5x	XXX	n/a	XXX	XXX	XXX
P/E	-8.6x	XXX	-9.8x	XXX	XXX	XXX
EV/FCF	-9.6x	XXX	-9.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Scancell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Scancell Margins & Growth Rates

Scancell's last 12 month revenue growth is -85%

Scancell's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Scancell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Scancell's rule of X is -652% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Scancell and other 15K+ public comps

Scancell Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-85%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-440%	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	2%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-652%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	312%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	413%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial